Im­muno­Gen shares tank (again) af­ter the FDA nix­es a shot at an OK for its armed an­ti­body in wake of a failed PhI­II

Im­muno­Gen $IMGN just com­pound­ed its woes with their lead drug. 

Two months af­ter ac­knowl­edg­ing that their an­ti­body-drug con­ju­gate mirve­tux­imab so­rav­tan­sine failed a Phase III study for ovar­i­an can­cer, the FDA has bat­ted back an at­tempt to hunt an ac­cel­er­at­ed ap­proval based on a sec­ondary end­point, send­ing their stock price tum­bling again.

The FDA now wants to see a new Phase III tri­al for the drug, which won’t be cheap or easy to pull off.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.